ALNY — ALNYLAM PHARMACEUTICALS, INC.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2016-01-04.
Performance
Technicals
Others in Healthcare
Measured signals that fired on ALNY
| date | signal | measured base rate |
|---|---|---|
| 2026-07-22 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
| 2026-07-13 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-07-09 | Equal highs taken out structure | -0.70% over 21 days · t = -8.28 · n = 68,636 statistically distinguishable from its control group |
| 2026-07-02 | Bollinger bandwidth breaks out of its own compression structure | -0.63% over 21 days · t = -2.80 · n = 7,196 statistically distinguishable from its control group |
| 2026-06-05 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-06-03 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-06-01 | PYOTT DAVID E I Director | Open-market sale 10b5-1 plan | 1.2K | 299.87 | 366.4K |
| 2026-06-01 | PYOTT DAVID E I Director | Open-market sale 10b5-1 plan | 1.2K | 298.91 | 351.2K |
| 2026-06-01 | PYOTT DAVID E I Director | Open-market sale 10b5-1 plan | 921 | 297.71 | 274.2K |
| 2026-06-01 | PYOTT DAVID E I Director | Open-market sale 10b5-1 plan | 495 | 300.72 | 148.9K |
| 2026-06-01 | PYOTT DAVID E I Director | Open-market sale 10b5-1 plan | 17 | 302.65 | 5.1K |
| 2026-06-01 | PYOTT DAVID E I Director | Option exercise 10b5-1 plan | 3.8K | 0.00 | 0 |
| 2026-05-20 | HAMBURG MARGARET A Director | Grant or award | 671 | 0.00 | 0 |
| 2026-05-20 | BRANDICOURT OLIVIER Director | Grant or award | 671 | 0.00 | 0 |
| 2026-05-20 | Ausiello Dennis A Director | Grant or award | 671 | 0.00 | 0 |
| 2026-05-20 | Arbuckle Stuart A Director | Grant or award | 671 | 0.00 | 0 |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| FMR LLC | 4.8B | 14.6M |
| Capital World Investors | 3.6B | 10.8M |
| BlackRock, Inc. | 3.5B | 10.4M |
| Capital Research Global Investors | 3.1B | 9.5M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2.1B | 6.5M |
| JPMORGAN CHASE & CO | 2.0B | 6.3M |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.0B | 5.9M |
| STATE STREET CORP | 1.1B | 3.3M |
| GEODE CAPITAL MANAGEMENT, LLC | 884.6M | 2.7M |
| BAILLIE GIFFORD & CO | 825.1M | 2.5M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- (NASDAQ: ALNY) Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. Investors to Contact the Firm · 2026-08-22
- Alnylam initiated an outperform at BMO on RNAi pipeline · 2026-08-19
- Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm · 2026-08-16
- Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing · 2026-08-16
Ask the AI about ALNY
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →